Pemetrexed (Alimta)
The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves
Current Oncology Reports 2026 June 8 [Link] Mehmet Kucukoner, Tarik Demir, Abduljalil Mohammed Alsubaie, Ulas Alabalik, Aisha K Ibrahim, Mariaelena Pierobon, Lance Liotta Abstract Purpose of review: Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum-pemetrexed chemotherapy has persisted as the…
Read MoreA single-center experience in parenchyma-sparing surgical treatment of malignant pleural mesothelioma
Updates in Surgery 2026 June 1 [Link] Giuseppe Mangiameli, Debora Brascia, Emanuela Re Cecconi, Veronica Maria Giudici, Edoardo Bottoni, Alessandro Crepaldi, Umberto Cariboni, Alberto Testori, Paolo Zucali, Matteo Perrino, Nadia Cordua, Armando Santoro, Marco Alloisio, Giuseppe Marulli Abstract The role of surgery in malignant pleural mesothelioma (MPM) remains controversial, particularly after the negative results of…
Read MoreEmerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview
Thoracic Cancer 2026 April [Link] Raffaella Pagliaro, Beatrice Leonardi, Angela Schiattarella, Grazia Bergameo, Carmine Picone, Adolfo Gallipoli D’Errico, Filippo Scialò, Fabio Perrotta, Maria Luisa De Rimini, Alfonso Fiorelli, Andrea Bianco Abstract Pleural mesothelioma (PM) is a rare and aggressive cancer arising from pleural mesothelial cells with a strong association to asbestos exposure. Among the diagnostic…
Read MoreMalignant mesothelioma of the tunica vaginalis testis: A case report
Oncology Letters 2026 March 4 [Link] Yuanchen Lu, Junjun Miu, Zhongru Fan, Zheng Zhi, Lei He, Junpeng Deng, Xianhua Shao, Jingqi Hua, Yichen Qian, Jianjun Xie Abstract Malignant mesothelioma of the tunica vaginalis testis (MMTVT) is a rare pathological entity. The present report describes the case of a patient who presented with insidious-onset right lower…
Read MoreTargeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma
Cell Death & Disease 2026 February 28 [Link] Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Md Towhid Ahmed Shihan, Nushrat Jahan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, Hideaki Ito, Yoshifumi Kaneko, Yinzhi Lin, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa Abstract Pleural mesothelioma (PM)…
Read MoreImmune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers
Current Oncology 2026 February 3 [Link] Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano Abstract Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum-pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous,…
Read MoreAnalysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study
Frontiers in Oncology 2026 February 3 [Link] Zhi-Ran Yang, Xin-Li Liang, Xin-Bao Li, Xin-Jing Zhang, He-Liang Wu, Yan-Dong Su, Yan Li, Song-Lin An Abstract Objective: To investigate the efficacy and safety of pemetrexed/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with malignant…
Read MoreOptimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies
Thorax 2026 February 17 [Link] Christophe Blanquart, Arnaud Scherpereel Abstract Background: Pleural mesothelioma (PM) is a rare tumour, usually associated with previous asbestos exposure. Standard frontline, pemetrexed/platinum-based chemotherapy has been challenged since 2020 by dual immunotherapy, that is, anti-programmed cell death-1 (anti-PD-1) + anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors and recently by combination of…
Read MoreSATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma
Cells 2026 February 2 [Link] Cynthia Brown, Shivam Srivastava, Rohit Srivastava, Rashmi Srivastava, Jason Morvant, Anju Shrivastava, Rakesh K Srivastava Abstract SATB2 (special AT-rich binding protein 2) functions as a chromatin-associated epigenetic regulator that modulates gene expression, in part by serving as a transcriptional cofactor. This study assessed whether SATB2 overexpression is sufficient to promote…
Read MoreValidation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models
Scientific Reports 2026 February 11 [Link] Huaikai Shi, Sakthi Priya Selvamani, Richard Zelei, Ling Zhuang, Dongwei Wang, Ben Johnson, Vivek Dharwal, Duo Xu, Yiwei Wang, Tristan Rutland, Sonja Klebe, Steven Kao, Anthony Linton, Elham Hosseini-Beheshti, Yuen Yee Cheng Abstract Pleural mesothelioma (PM) is a highly aggressive cancer with limited treatment efficacy and poor prognosis. Conventional…
Read More
Skip to content